CHICAGO, IL and AUSTIN, TX; , June 05, 2017 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”) today announced that data from the company’s non-aqueous, room temperature stable, ready to use liquid glucagon formulation, including the auto-injector pen, and mini-dose pen offerings will be presented in three different posters during the 77 th American Diabetes Association Scientific Sessions Conference in San Diego from June 9 th to 13 th .
The following posters will be presented:
Title: A Pilot Study in Adults with T1DM to Examine the Efficacy of Stable Non-Aqueous Glucagon for Treatment of Severe Hypoglycemia Authors: Mark Christiansen, Diablo Clinical Research, Walnut Creek CA; Martin J. Cummins, Steven Prestrelski, Xeris Pharmaceuticals, Inc., Austin, TX; Leon Shi, Poul Strange, Integrated Medical Development, Princeton Junction, NJ Poster #: 140-LB General Poster Session: Sunday June 11, 2017 from 12:00 – 1:00 PM in Hall B Research supported by: Xeris Pharmaceuticals, Inc.
Title: Efficacy and Safety of Mini-dose Glucagon for Treatment of Non-Severe Hypoglycemia in Adults with Type 1 Diabetes Authors: Morey W. Haymond, MD, Baylor College of Medicine, Houston, TX; Michael R. Rickels, MD, MS, Shivani Agarwal, MD, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Howard Wolpert, MD, Joslin Diabetes Center, Harvard Medical School, Boston, MA; Viral N Shah, MD, Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO; Jennifer L. Sherr, MD, PhD, Yale School of Medicine, New Haven, CT; Ruth S. Weinstock, MD, PhD, SUNY Upstate Medical University, Syracuse, NY; Martin J. Cummins, BS, Brett Newswanger, MBA, Xeris Pharmaceuticals Inc, Austin TX; Alandra S. Verdejo, MPH, Stephanie N. DuBose, MPH, and Roy W. Beck, MD, PhD, Jaeb Center for Health Research; for the T1D Exchange Mini-dose Glucagon Study Group Poster #: 1068-P Moderated Poster Session: Saturday June 10, 2017 from 12:30 – 1:30 PM in Hall B General Poster Session: Sunday June 11, 2017 from 12:00 – 1:00 PM in Hall B Research supported by: The Leona M. and Harry B. Helmsley Charitable Trust
Title: Mini-dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes Authors: Michael R. Rickels, MD, MS, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Stephanie N. DuBose, MPH, Roy W. Beck, MD, PhD, Jaeb Center for Health Research, Tampa, FL; Howard Wolpert, MD, Elena Toschi, MD, Joslin Diabetes Center, Harvard Medical School, Boston, MA; Martin J. Cummins, BS, Brett Newswanger, MBA, Xeris Pharmaceuticals, Inc., Austin, TX; and Michael C. Riddell, PhD, School of Kinesiology and Health Science, Muscle Health Research Centre, York University, Toronto, ON; for the T1D Exchange Mini-Dose Glucagon Study Group
Poster #: 67-LB General Poster Session: Sunday June 11, 2017 from 12:00 – 1:00 PM in Hall B Research supported by: The Leona M. and Harry B. Helmsley Charitable Trust
The posters will be on display Saturday, June 10 th at 10:00 a.m. until Monday, June 12 th at 2:00 PM.
About the ADA Scientific Sessions The 77 th American Diabetes Association’s Scientific Sessions will offer researchers and health care professionals from around the world the unique opportunity to share ideas and learn about the significant advances in diabetes research, treatment, and care. Attendees will have access to more than 3,000 original research presentations, take part in provocative and engaging exchanges with leading diabetes experts, and expand their professional networks.
About Glucagon Glucagon is a metabolic hormone secreted by the pancreas that raises blood glucose levels by causing the liver to rapidly convert glycogen (the stored form of glucose) into glucose, which is then released into the bloodstream. Glucagon and insulin are two critical hormones in a glycemic control system that keeps blood glucose at the right level in healthy individuals. In people with diabetes who are dependent on insulin, this control system is disrupted and insulin must be injected prior to meals to avoid high levels of blood glucose (hyperglycemia). The opposite effect of low blood glucose (hypoglycemia) is also prevalent in this population due to dysregulated glucagon secretion. Severe hypoglycemia is a serious condition and can lead to seizures, coma, potential brain injury and, if untreated, death. Xeris proprietary formulation technology has the potential to provide the first soluble, stable, ready-to-inject glucagon for use by people with diabetes and other indications to prevent or manage both moderate and severe hypoglycemia, and achieve optimal glucose control.
About Xeris Pharmaceuticals, Inc. Xeris is a Chicago, IL and Austin, TX-based, specialty biopharmaceutical company developing improved and differentiated injectable therapeutics for multiple indications including diabetes. The company's proprietary XeriSol™ and XeriJect™ formulation technologies allow for the subcutaneous and intradermal delivery of highly concentrated, non-aqueous, ready-to-use formulations of peptides, proteins, antibodies and small molecules using auto-injectors, multi-dose pens and pumps. Xeris' proprietary formulation platforms have the potential to offer distinct advantages over existing products and formulations including: up to 1000-fold lower injection volumes, long term room-temperature stability, elimination of reconstitution and refrigeration, all of which can lead to products that are easier to use by patients, caregivers, health practitioners, and can reduce costs for payers and the healthcare system. For more information please visit the Xeris website at: www.xerispharma.com .
Xeris Media Contact Brad Huckabee Xeris Pharmaceuticals, Inc. www.xerispharma.com
